|
| Figure 1: Mean (SD) plasma concentration-time profiles for canagliflozin following administration of two canagliflozin/metformin FDC IR tablets (A) 50 mg/500 mg (B) 50 mg/850 mg and (C) 50 mg/1,000 mg and coadministration of canagliflozin + metformin IR individual tablets (A) 100 mg + 2x 500 mg (B) 100 mg + 2x 850 mg and (C) 100 mg + 2x 1,000 mg (Studies 1-3). |
